Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
François Raffi, Sharon Walmsley(University Health Network), Joseph J. Eron(University of North Carolina at Chapel Hill), Keith A. Pappa(Research Triangle Park Foundation), Robert L. Cuffe(University of Oxford), Steve Almond(GlaxoSmithKline (Canada)), Keikawus Arastéh(Auguste-Viktoria-Klinik), Anita Rachlis(University of Toronto), Cynthia Brinson, Clare Brennan(Research Triangle Park Foundation), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), W. Garrett Nichols(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Catherine Granier(GlaxoSmithKline (United Kingdom))
Cited by 57
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2012|2.5k
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k